Creation of the first spin-off company by CING
Following the development by the Research Team of Prof Philippos Patsalis, of the innovative test for the non-invasive prenatal diagnosis for Down Syndrome, the Institute proceeded with the creation of its first spin-off company “NIPD Genetics Ltd” based near the CING premises in Nicosia. NIPD Genetics Ltd successfully raised the funds required (€2.500.000) through 18 investors from Cyprus and abroad.
The Chief Executive Director of the Company is Prof Philippos Patsalis, and the Members of the Board of Directors are Mr Michalis Sarris (President), Prof Philippos Patsalis, Mr Chris Phylactou, Prof Peter Coggins and Dr Nicos Michaelas. The Company initiated its activities in October 2011 with a 9-member team, aiming initially for the development and production of an NIPD Kit for Down Syndrome and eventually for other genetic diseases.
Click here to access the NIPD Genetics Ltd web site